What can be expected from the development of preventive vaccines for non virally-induced cancers?

The introduction of prophylactic vaccines for virally-induced cancers (primarily HBV and HPV) has achieved a tremendous impact on disease related deaths. This has, in time, raised interest in developing vaccines to intercept pre-cancerous cells based on their expression of aberrant self-antigens (e.g. hypoglycosilated MUC1 in colon, lung and breast carcinomas). As of 2024, a number of phase I clinical studies have been ongoing in the USA, for both primary prevention and early cancer interception in genetically susceptible individuals (e.g. Kras and BRCA1/2 mutation carriers, Lynch syndrome). For more details, please check 
Stanton et al. Advances and challenges in cancer  immunoprevention and  immune interception.  J Immunother Cancer 2024
McKeague et al. Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions. Antibodies (Basel), 2024